LENZ Therapeutics (LENZ) Cash from Investing Activities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash from Investing Activities data on file, last reported at $33.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 75.56% year-over-year to $33.2 million in Q1 2026; TTM through Mar 2026 was -$61.4 million, a 60.03% increase from a year earlier, with the FY2025 full-year figure at -$75.7 million, up 51.02% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $33.2 million, up from -$89.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for LENZ reached as high as $33.2 million in Q1 2026 and fell as low as -$170.7 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$27.6 million across 5 years, with a median of -$4.3 million in 2025.
• Across the five-year window, Cash from Investing Activities plunged 47307.22% in 2022 and jumped 300100.0% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $13.5 million in 2022, then advanced by 12.19% to $15.2 million in 2023, then sank by 178.18% to -$11.9 million in 2024, then sank by 657.06% to -$89.8 million in 2025, then surged by 136.92% to $33.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $33.2 million in Q1 2026, -$89.8 million in Q4 2025, and -$4.3 million in Q3 2025.